TNF-α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis.

Frederic HilezianAdil MaaroufClemence BoutiereAudrey RicoSarah DemortierePhilippe KerschenThomas SeneCaroline Bensa-KoscherClaire GiannesiniJean CapronArsene MekinianJean-Philippe CamdessanchéGéraldine AndrodiasRomain MarignierNicolas CollonguesOlivier CasezCatalina CoclituMathieu VaillantGuillaume MatheyJonathan CironJean PelletierBertrand Audoinnull null

Published in: Journal of neurology, neurosurgery, and psychiatry (2021)

This study provides Class IV evidence that TNF-α inhibitor used as steroid-sparing monotherapy is effective for patients with CNS parenchymal sarcoidosis.

Keyphrases

rheumatoid arthritis
combination therapy
blood brain barrier
robot assisted
open label
clinical trial